FindTrial
Sign In

Therapeutic efficacy of olmesartan, telmisartan and amlodipine to compare with histologic improvement and addciation about AGTR1 gene polymorphisms in subjects with nonalcoholic steatohepatitis (NASH); randomized open-labeled prospective study.

Therapeutic efficacy of olmesartan, telmisartan and amlodipine to compare with histologic improvement and addciation about AGTR1 gene polymorphisms in subjects with nonalcoholic steatohepatitis (NASH); randomized open-labeled prospective study. - Therapeutic efficacy of olmesartan, telmisartan and amlodipine in subjects with nonalcoholic steatohepatitis (NASH)

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001587
Enrollment
60
Registered
2008-12-25
Start date
2008-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic steatohepatitis

Interventions

administration of olmesartan (40mg daily) in 24 weeks. administration of telmisartan (40mg daily) in 24 weeks. administration of amlodipine (7.5mg daily) in 24 weeks.

Sponsors

Yokohama City University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: a.All patients complicate hypertension (sBP 140-179mmHg, dBP 90-109mmHg ) b.The biopsy-proven nonalcoholic steatosis(NASH) patient will be evaluated in this study. c. All patients gave their written informed consent to participation in the study.

Exclusion criteria

Exclusion criteria: 1)The patient with diabetes mellitus(HbA1c>6.2) 2) contraction of renal artery. 3) The criteria for exclusion from participation in the study: history of hepatic disease, such as chronic hepatitis C or concurrent active hepatitis B (serum positive for hepatitis B surface antigen), autoimmune hepatitis, primary biliary cirrhosis (PBC), sclerosing cholangitis, hemochromatosis, wilsons disease, and current or past consumption of more than 20g of alcohol daily. 4) an anamnesis of drug allergy to use.

Design outcomes

Primary

MeasureTime frame
Before and after 6 months of medication to nonalcoholic statohepatitis (NASH) patients, we assessed liver lipid-metabolite alteration for use minute lipid analyzer: LipoSEARCH, hepatic histologic features,and AGTR1 gene polymorphisms.—

Secondary

MeasureTime frame
To measure the factors about NASH progressive marker as glucose and lipid metabolite, oxidative stress, visceral/subcutaneous fat area,liver TG content.—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026